Aidoc is a technology company.
Aidoc has raised $344.0M across 7 funding rounds.
Key people at Aidoc.
Aidoc has raised $344.0M in total across 7 funding rounds.
Aidoc has raised $344.0M in total across 7 funding rounds.
Aidoc's investors include Alpha Intelligence Capital, Bond, General Catalyst, Khosla Ventures, LGF, Sapphire Ventures, Square Peg Capital, TCV, TLV Partners, Transformation Capital, Danny Hadar, Uday Sandhu.
Key people at Aidoc.
Aidoc is an Israeli-founded technology company specializing in clinical AI solutions for healthcare, primarily focusing on AI-powered medical imaging analysis to detect acute conditions from CT scans and streamline workflows.[1][2][4] Its core product is the aiOS™ platform, an enterprise operating system that integrates FDA-cleared AI algorithms, supports real-time monitoring, and enables seamless hospital system interoperability, serving over 45 million patients annually across 1,200+ medical centers and 150+ health systems worldwide, including top U.S. hospitals like Mount Sinai and Yale New Haven.[1][3][5] Aidoc targets radiologists, cardiologists, neurologists, and care teams, solving critical problems like diagnostic delays, fragmented workflows, and preventable care gaps by prioritizing urgent findings and activating teams for faster interventions, which improves patient outcomes and operational efficiency.[2][4][6] With $370M in total funding, including a recent $150M round, Aidoc reports $95M revenue and plans to expand to 100 million patients in three years via its CARE foundation model.[1][3][6]
Founded in 2016 in Israel, Aidoc began by commercializing a single AI product for radiologists to detect critical conditions on CT scans, evolving rapidly into a comprehensive platform analyzing 20+ conditions across 900+ global hospitals.[1][5] Key leadership includes CEO Elad Walach, who drives the mission to reduce diagnostic errors and empower physicians.[3][6] Early traction came from FDA clearances—now at 18, the most in clinical AI—and deployments in seven of the top ten U.S. hospitals, building on partnerships with NVIDIA and AWS for scalable AI development.[1][3][5] Pivotal moments include shifting from point solutions to a multisided aiOS™ ecosystem hosting partner algorithms and the 2025 $150M funding for CARE, compressing years of roadmap into faster innovation for oncology and cardiovascular expansion.[3][6]
Aidoc rides the clinical AI wave in healthcare, addressing fragmented systems and diagnostic errors amid rising imaging volumes and staffing shortages, with timing amplified by post-pandemic demands for efficiency and AI regulatory progress (e.g., FDA clearances).[1][4][5] Market forces like high-performance computing from NVIDIA/AWS and foundation models like CARE favor Aidoc, enabling scalable, "always-on" intelligence that unifies silos across specialties.[3][6] It influences the ecosystem by pioneering hospital-centric platforms, fostering multi-vendor AI adoption (BRIDGE guidelines with NVIDIA), and partnering with 150+ systems to set standards for accountable AI deployment, accelerating broader healthcare transformation.[1][6]
Aidoc is poised to dominate clinical AI with CARE expanding to 90% disease coverage and 100M patients in three years, prioritizing oncology and cardiovascular while growing its open aiOS™ ecosystem.[3][6] Trends like multimodal AI, real-time inference, and regulatory maturity will propel it, potentially evolving from radiology-focused to a full-spectrum care platform influencing global standards. As AI becomes foundational to every patient encounter, Aidoc's trajectory reinforces its role as a pioneer, transforming reactive healthcare into proactive, outcome-driven systems.[3][6]
Aidoc has raised $344.0M across 7 funding rounds. Most recently, it raised $110.0M Venture Round in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $110.0M Venture Round | Alpha Intelligence Capital, Bond, General Catalyst, Khosla Ventures, LGF, Sapphire Ventures, Square Peg Capital, TCV, TLV Partners, Transformation Capital, Danny Hadar, Uday Sandhu | |
| Jun 1, 2022 | $110.0M Series D | Alpha Intelligence Capital, General Catalyst, Square Peg Capital, TCV, TLV Partners, Danny Hadar, Uday Sandhu | |
| Jul 1, 2021 | $66.0M Series C | Bond, General Catalyst, Khosla Ventures, LGF, Sapphire Ventures, Transformation Capital | |
| Sep 1, 2020 | $20.0M Series B | Alpha Intelligence Capital, General Catalyst, Square Peg Capital, TCV, TLV Partners, Danny Hadar, Malek Meslemani, Uday Sandhu | |
| Apr 1, 2019 | $27.0M Series B | Alpha Intelligence Capital, General Catalyst, Shasta Ventures, Square Peg Capital, TCV, TLV Partners, Danny Hadar, Paul Holland, Uday Sandhu | |
| Apr 1, 2017 | $7.0M Series A | Shasta Ventures, TLV Partners, Paul Holland | |
| Oct 1, 2016 | $4.0M Seed | TLV Partners |
